Modus Therapeutics to Present LPS Study Data at Pharmacology 2024

Stockholm, December 10, 2024 – Modus Therapeutics announces that data from its Phase 1b LPS study will be presented as a poster at the British Pharmacological Society Annual Meeting (Pharmacology 2024) in Harrogate, UK, on December 10–12. The study data that was disclosed in reporting during 2023, explores the effects of sevuparin, on local and systemic inflammation induced by the bacterial toxin lipopolysaccharide (LPS) in healthy volunteers.

The poster, titled "Sevuparin effects on local and systemic LPS-induced inflammation in healthy volunteers," summarizes results from the randomized, double-blind, placebo-controlled Phase 1b study in 71 healthy participants and will be presented by Dr de Bruin from our collaborators at the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands.

Key findings as previously reported from the study include:

• Sevuparin was well tolerated across all dose groups, with no clinically relevant adverse effects.
• In the systemic LPS challenge, sevuparin significantly increased circulating levels of basophils, neutrophils, and lymphocytes at the highest dose level.
• A near significant effect of sevuparin was observed on respiratory rate.
• No significant differences compared to placebo were observed for other systemic or local measures.

“This poster presentation underlines the maintained interest in the effects observed in this study, and together with the favorable safety profile of sevuparin, it underlines our unchanged confidence in its potential as a treatment for acute inflammatory conditions such as sepsis and endotoxemia,” said John Öhd, CEO of Modus Therapeutics.

The poster will be presented on December 10 from 13:45 to 15:15 CET.

Modus Therapeutics continues to evaluate sevuparin’s role in addressing significant medical needs and looks forward to sharing further updates on its clinical development.

For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

About Modus Therapeutics and sevuparin
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.